External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><div><div><div><ul><li>PYC provided an update to its existing VP-001 Phase I/II dataset in RP11 (Retinitis Pigmentosa 11), a rare blinding eye disease, to be presented this weekend at AVPRS (Congress of the Asia-Pacific Vitreo-Retina Society).</li><li>Data were broadly positive, noting the full dataset is still incomplete, especially out at the six-month timepoint.</li><li>Net-net, we view the consistency in benefit across LLVA (low luminance visual acuity), and reduced number of scotomas (blind spots) as a positive sign that VP-001 is having a positive impact on functional outcomes. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC provided an update to its existing VP-001 Phase I/II dataset in RP11 (Retinitis Pigmentosa 11), a rare blinding eye disease, to be presented this weekend at AVPRS (Congress of the Asia-Pacific Vitreo-Retina Society).Data were broadly positive, noting the full dataset is still incomplete, especially out at the six-month timepoint.Net-net, we view the consistency in benefit across LLVA (low luminance visual acuity), and reduced number of scotomas (blind spots) as a positive sign that VP-001 is having a positive impact on functional outcomes. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - Net Positive VP-001 Update at APVRS